EAA supplements and muscle gain in postmenopausal women: what the data shows

What did @drjenashton actually say?

Dr. Jen Ashton reviewed a newly published Korean randomized controlled trial from the Journal of the International Society of Sports Nutrition. The study split postmenopausal women into four groups: control, resistance training alone, essential amino acids (EAA) alone at 11g/day, and a combined resistance training plus EAA group. She reported that the combination group produced the most dramatic results, including a "113% increase in the thalastatin myostatin ratio" (she means follistatin-to-myostatin ratio), significant drops in myostatin, and reductions in inflammatory cytokines TNF-alpha, IL-6, and IL-1 beta. Her core argument: pairing weights with EAA supplementation beats either intervention alone for fighting sarcopenia and age-related inflammation. That is a fair summary of what the study appears to show.

Does the science back this up?

The short answer is mostly yes, with some important caveats about scale and population. The mechanistic story she tells is real. Myostatin is a well-characterized negative regulator of skeletal muscle mass, and follistatin is its biological antagonist. Resistance exercise is among the most reliably documented ways to suppress myostatin (Willoughby, 2004, Medicine and Science in Sports and Exercise). EAA supplementation, particularly leucine-rich formulas, drives mTORC1 signaling and muscle protein synthesis independently (Wolfe, 2017, Journal of Nutrition). That these two interventions compound each other is biologically plausible and consistent with prior mechanistic data. The cytokine reductions she cites, particularly in TNF-alpha and IL-6, also align with established exercise immunology literature. IL-6 is complicated here: it is both pro-inflammatory systemically and released acutely from contracting muscle as a myokine with anti-inflammatory effects, a nuance the video skips entirely.

What did they get wrong (or right)?

The biggest error is the name. She repeatedly calls it "thalastatin," which is not a real biological term. The compound she means is follistatin, which is also the hashtag she used. This is not a trivial slip. Follistatin is a specific secreted glycoprotein with a defined receptor-binding mechanism, and mispronouncing or misnaming it in a video with 25,000 views creates genuine confusion for viewers trying to research this independently. Credit where it is due: her interpretation of the follistatin-to-myostatin ratio as reflecting anabolic-to-catabolic balance is conceptually accurate. She also correctly identified this as an RCT, correctly reported the four-arm design, and did not overstate the findings as a cure for anything. The claim that the combo group showed the "most pronounced improvement" appears to be a direct read of the study data, not editorializing. She deserved more scrutiny on the IL-6 point. Framing IL-6 reduction as purely anti-inflammatory in an exercise context misses the muscle-derived IL-6 story documented by Pedersen and Febbraio (2008, Nature Reviews Immunology).

What should you actually know?

This study adds to a growing body of evidence that combined mechanical and nutritional stimuli outperform either alone in older adults, a finding consistent with meta-analyses by Morton et al. (2018, British Journal of Sports Medicine) on protein supplementation during resistance training. But there are real limitations worth naming. This trial was conducted in Korean postmenopausal women, a specific demographic, and extrapolating directly to other populations requires caution. The 11g EAA dose matters: not all amino acid supplements are formulated the same way, and leucine content in particular drives anabolic signaling. The 12-week timeframe also limits what we can say about long-term durability of these changes. If you are postmenopausal and considering EAA supplementation alongside a resistance training program, this is encouraging data. It is not, however, a prescription. Work with a clinician who can assess your individual protein needs, training status, and inflammatory markers before adding any supplement protocol.

Does this connect to peptide research?

The video is categorized under peptide therapy, and the follistatin angle is relevant here. Follistatin peptide analogs have been explored in preclinical research as potential myostatin inhibitors, though no follistatin-based peptide therapy is currently FDA-approved for human use. The study itself used dietary EAAs, not peptide injections, and Dr. Ashton made no peptide claims. Connecting this study to peptide optimization protocols would require a significant leap beyond the data. The more honest read is that this research supports diet and exercise as the primary levers for myostatin suppression and follistatin elevation in this population, full stop.